Abstracts tagged "Rheumatology"

Abstract Number: 0205 • ACR Convergence 2021
An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study
Ediz Dalkilic¹, Dilek Solmaz², Orhan Kucuksahin³, Erhan Capkin⁴, Mehmet Emin Derin⁵, Didem Arslan⁶, Fatih Noyan⁷, Nihan Belkis Coskun¹, Sadiye Murat⁸, Omer Faruk Sendur⁹, Meltem Alkan Melikoglu¹⁰, Savas Gursoy¹¹, Taciser Kaya¹², Ali Sahin¹³, Murat Karkucak⁴, Timur Pirildar¹⁴, Mustafa Ender Terzioglu¹⁵, Cemal Bes¹⁶ and Servet Akar², ¹Uludag University, School of Medicine – Bursa, Turkey, Bursa, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Ankara State Hospital, School of Medicine, Ankara, Turkey, ⁴Karadeniz Technical University, School of Medicine, Trabzon, Turkey, ⁵Sivas Numune Hospital, Sivas, Turkey, ⁶Cukurova University, School of Medicine – Adana, Turkey, Adana, Turkey, ⁷Nazilli State Hospital – Aydın, Turkey, Aydin, Turkey, ⁸Istanbul Medeniyet University, Goztepe Training and Research Hospital, İstanbul, Turkey, ⁹Adnan Menderes University, School of Medicine, Aydin, Turkey, ¹⁰Ataturk University, School of Medicine, Erzurum, Turkey, ¹¹Gaziantep University, School of Medicine – Gaziantep, Turkey, Gaziantep, Turkey, ¹²Saglik Bilimleri University, Izmır Bozyaka Trainig and Research Hospital – Izmir, Turkey, Izmir, Turkey, ¹³Sivas Cumhuriyet University, School of Medicine, Sivas, Turkey, ¹⁴Celal Bayar University, School of Medicine – Manisa, Turkey, Manisa, Turkey, ¹⁵Akdeniz University, School of Medicine, Antalya, Turkey, ¹⁶Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Available evidence suggests that timely and effective management of patients with psoriatic arthritis (PsA) can improve long-term outcomes. Current information on the factors which…
Abstract Number: 1082 • ACR Convergence 2021
The Rheumatology Workforce in Canada: Results of the Workforce and Wellness Survey
Stephanie Kulhawy-Wibe¹, Jessica Widdifield², Jason Kur³, Jennifer Lee⁴, Carter Thorne⁵, Elaine Yacyshyn⁶, Michelle Batthish⁷, Dana Jerome⁴, Rachel Shupak⁸, Konstantin Jilkine⁹, Jane Purvis¹⁰, Justin Shamis⁴, Janet Roberts¹¹, Jennifer Burt¹², Nicole Johnson¹, Cheryl Barnabe¹, Nicole Spencer¹ and Claire Barber¹, ¹University of Calgary, Calgary, AB, Canada, ²Sunnybrook Research Institute; ICES; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷McMaster University, Hamilton, ON, Canada, ⁸St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Peterborough Education, Peterborough, ON, Canada, ¹¹Dalhousie University, Halifac, NS, Canada, ¹²Eastern Health, St. John's, NL, Canada
Background/Purpose: A rheumatology workforce survey conducted in Canada in 2015 predicted a looming critical shortage of rheumatologists, with one third of surveyed rheumatologists indicating plans…
Abstract Number: 2093 • 2019 ACR/ARP Annual Meeting
Safety of Adjuvanted Herpes Zoster Subunit Vaccine (HZ/su, Shingrix) Among Patients with Autoimmune Inflammatory Diseases
Saurav Acharya¹, Syed Raza ¹, Debendra Pattanaik ¹ and Alexis Howard ², ¹University of Tennessee Health Science Center, MEMPHIS, TN, ²University of Tennessee Health Science Center, Memphis
Background/Purpose: HZ/su has been in use since 2017 and is recommended by the advisory committee on immunization practices (ACIP) as the preferred shingles vaccine due…
Abstract Number: 2304 • 2019 ACR/ARP Annual Meeting
Bone Microstructure of Patients with Rheumatoid Arthritis: A HR-pQCT Study
Ikuko Tanaka¹, Takashi Kato ², Hiroaki Mizuno ³, Ryosuke Hibi ³, Motoaki Kai ⁴, Kunikazu Ogawa ⁴, Hisaji Ohshima ⁵ and Shigenori Tamaki ³, ¹Nagoya Rheumatology Clinic, Ngoya, Japan, ²National Center for Geriatrics and Gerontology, Obu, Japan, ³Nagoya Rheumatology Clinic, Nagoya, Japan, ⁴Mie Rheumatology Clinic, Suzuka, Japan, ⁵National Tokyo Medical Center, Tokyo, Japan
Background/Purpose: In rheumatoid arthritis (RA), it has been reported that osteoclast are activated by immune complexes, anti-CCP antibodies (ACPAs), and inflammatory cytokines. The purpose of…
Abstract Number: 155 • 2019 ACR/ARP Annual Meeting
A Prospective, Unblinded, Non-randomized Pilot Study Examining the Effect of a Musculoskeletal Immersion Curriculum for First Year Internal Medicine Residents
Eric Miller¹, Linh Ngo ², Zaki Abou Zahr ², Cassedy Mahrer ³ and Rawad Nasr ³, ¹University of Minnesota, Woodbury, MN, ²Hennepin Healthcare, Minneapolis, MN, ³Hennepin Healthcare, Minneapolis
Background/Purpose: Musculoskeletal (MSK) disorders are one of the most common clinic visit complaints. Prior studies evaluating graduate medical training of rheumatology and MSK medicine have…
Abstract Number: 259 • 2019 ACR/ARP Annual Meeting
Describing Treatment Patterns and Healthcare Costs in Newly Diagnosed Psoriatic Arthritis Patients by Physician Specialty
Joseph Tkacz ¹, Ervant Maksabedian², Philip Chan ¹, Brendan Limone ¹, Alexis Ogdie ³, Elaine Karis ⁴ and Bradley Stolshek ², ¹IBM Watson, Bethesda, MD, ²Amgen Inc., Thousand Oaks, CA, ³University of Pennsylvania, Philadelphia, PA, ⁴Amgen Inc, Thousand Oaks, CA
Background/Purpose: The clinical heterogeneity of psoriatic arthritis (PsA) presents a variety of diagnostic and treatment challenges, which may be reflected in the way different health…
Abstract Number: 1213 • 2019 ACR/ARP Annual Meeting
A Retrospective Review and Prospective Intervention for Outpatient Follow-Up of Hospitalized Patients in Rheumatology
Shakaib Hayat¹ and Stanley Ballou ², ¹Case Western Reserve University (MetroHealth), Cleveland, OH, ²Metrohealth medical center, Cleveland, OH
Background/Purpose: There is lack of appropriate outpatient follow-up (F/U) for hospitalized rheumatology patients, which can result in disease recurrence and recurrent inpatient admissions1. This is…
Abstract Number: 191 • 2018 ACR/ARHP Annual Meeting
Creation of an Immunology Series Video Library in Facilitating Basic Immunology Knowledge Acquisition and Retention Amongst Adult Rheumatology Trainees
Megan Himmel¹, Nigil Haroon^2,3, Wendy Gu⁴, Arthur Bookman^2,4, Heather Mcdonald-Blumer⁵ and Dharini Mahendira^4,6, ¹Internal Medicine, University of Toronto, Toronto, ON, Canada, ²Toronto Western Hospital, Toronto, ON, Canada, ³Rheumatology, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, University of Toronto, Toronto, ON, Canada, ⁶St. Michael's Hospital, Toronto, ON, Canada
Background/Purpose: A strong foundational knowledge in immunology is key to understanding complex rheumatologic disease processes. Indeed, an immunology curriculum delivered by Rheumatology training programs across…
Abstract Number: 97 • 2017 ACR/ARHP Annual Meeting
Medical Student Interest in Rheumatology As a Career
Peter Berger¹, Adey Berhanu², Derek Jones¹, Sean McNish³ and Victoria K. Shanmugam², ¹The George Washington University, Washington, DC, ²Rheumatology, The George Washington University, Washington, DC, ³Division of Rheumatology, The George Washington University, Washington, DC
Background/Purpose: Based on data from the Rheumatology Workforce Study, there are insufficient rheumatologists to serve the needs of the population. Little is currently known about…
Abstract Number: 912 • 2017 ACR/ARHP Annual Meeting
Has the Attractiveness of a Career in Rheumatology Changed for the Better? Comparison of Trends in the Rheumatology Fellowship Match from 2014 to 2017 with 2008 to 2013
Huynh Tran¹ and Richard Panush², ¹Special Project Manager, University of Southern California, Los Angeles, CA, ²Rheumatology, Program Director, University of Southern California, Los Angeles, CA
Background/Purpose: Rheumatology has been a less attractive career choice than most other medical subspecialties for many years. The 2015 American College of Rheumatology (ACR)…
Abstract Number: 2046 • 2017 ACR/ARHP Annual Meeting
Development and Validation of a Rheumatologist Satisfaction with Practice Scale –“ the Rheumatologist Satisfaction Scale” (RSS)
Khushboo Sheth¹, Antonia Valenzuela², Stanford Shoor³, Philip L. Ritter³ and Kate Lorig⁴, ¹Immunology & Rheumatology, Stanford University, Stanford, CA, ²Immunology and Rheumatology, Stanford University, Palo Alto, CA, ³Immunology & Rheumatology, Stanford University, Palo Alto, CA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Practice improvement research routinely measures patient satisfaction and disease-specific outcomes but seldom considers the satisfaction of physicians who deliver the care. Studies suggest that…
Abstract Number: 1585 • 2016 ACR/ARHP Annual Meeting
Previous Use of Conventional Disease-Modifying Antirheumatic Drugs and Response to Baricitinib
Arthur F. Kavanaugh¹, Ronald F. van Vollenhoven², David Muram³, Jahangir Alam³, Vipin Arora³, Ana Luisa de Macedo Pinto Correia³, Inmaculada de la Torre^3,4 and James R. O'Dell⁵, ¹UC San Diego School of Medicine, La Jolla, CA, ²Rheumatology Unit, Karolinska University Hospital, Solna, Sweden, ³Eli Lilly and Company, Indianapolis, IN, ⁴Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, ⁵Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Baricitinib (BARI), an oral JAK1/JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA.1,2 The purpose of this post hoc analysis…
Abstract Number: 1586 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs: A United States Subpopulation Analysis from Two Phase 3 Trials
Alvin F. Wells¹, Maria Greenwald², John D. Bradley³, Jahangir Alam³, Vipin K. Arora³ and Cynthia E. Kartman³, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²Desert Medical Advances, Palm Desert, CA, ³Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari), an oral selective JAK1 and JAK2 inhibitor, has been shown to be safe and efficacious compared to placebo (PBO) in two Phase…
Abstract Number: 1590 • 2016 ACR/ARHP Annual Meeting
Safety and Efficacy of Baricitinib in Elderly Patients with Moderate to Severe Rheumatoid Arthritis
Roy Fleischmann¹, Jahangir Alam², Vipin Arora², John D. Bradley², Douglas E. Schlichting² and David Muram², ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib (bari), an oral JAK1 and JAK2 inhibitor, is in development for patients (pts) with moderate to severe RA. Drug-related problems are common in…
Abstract Number: 1591 • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Switching from Adalimumab to Baricitinib: Phase 3 Data in Patients with Rheumatoid Arthritis
Peter C. Taylor¹, Edward Keystone², Robert Ortmann³, Maher Issa³, Li Xie³, David Muram³, John D. Bradley³, Stephanie de Bono³, Terence Rooney³ and Yoshiya Tanaka⁴, ¹Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Eli Lilly and Company, Indianapolis, IN, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Baricitinib (bari) is an oral JAK1/JAK2 inhibitor under investigation for the treatment of patients (pts) with moderate to severe RA.1-2 In the 52-week Phase…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].